Cytokinetics, Inc. Stock Nasdaq
Stocks
US23282W1009
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| Market Cap | 9.15B 8.05B 7.59B 6.92B 12.94B 878B 13.04B 91.04B 35.28B 447B 34.35B 33.61B 1,455B | P/E 2026 * |
-10.7x | P/E 2027 * | -14.4x |
|---|---|---|---|---|---|
| Enterprise Value | 7.99B 7.03B 6.62B 6.04B 11.3B 767B 11.39B 79.48B 30.8B 390B 29.99B 29.34B 1,270B | EV / Sales 2026 * |
53.3x | EV / Sales 2027 * | 19x |
| Free-Float |
98.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytokinetics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 01/01/2007 |
Sung Lee
DFI | Director of Finance/CFO | 55 | 08/05/2024 |
Eric Brown
COO | Chief Operating Officer | - | 01/03/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 01/01/2007 |
John Henderson
CHM | Chairman | 81 | 08/04/2022 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 09/02/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.30% | +2.97% | +54.99% | +104.15% | 74.18B | |
| -0.12% | -3.82% | +34.21% | +74.94% | 59.55B | |
| +2.04% | -2.71% | -14.45% | +367.88% | 25.84B | |
| +1.36% | +1.18% | +0.07% | -3.20% | 24.73B | |
| -1.05% | +1.07% | +21.45% | -10.04% | 20.87B | |
| -1.70% | -4.15% | +147.82% | +325.69% | 15.32B | |
| +1.89% | -2.04% | +47.25% | +162.46% | 14.06B | |
| -0.36% | -6.97% | -19.59% | +758.59% | 13.12B | |
| +0.41% | -3.30% | +21.06% | +242.35% | 11.85B | |
| Average | -0.10% | -0.80% | +32.53% | +224.76% | 28.84B | |
| Weighted average by Cap. | -0.73% | -0.22% | +35.12% | +159.94% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 150M 132M 124M 113M 212M 14.38B 214M 1.49B 578M 7.32B 562M 550M 23.81B | 425M 374M 352M 321M 601M 40.78B 606M 4.23B 1.64B 20.75B 1.59B 1.56B 67.54B |
| Net income | -809M -712M -671M -612M -1.14B -77.67B -1.15B -8.05B -3.12B -39.53B -3.04B -2.97B -129B | -649M -571M -538M -491M -919M -62.32B -926M -6.46B -2.5B -31.72B -2.44B -2.38B -103B |
| Net Debt | -1.16B -1.02B -964M -879M -1.64B -112B -1.66B -11.56B -4.48B -56.77B -4.36B -4.27B -185B | -1.06B -935M -882M -805M -1.5B -102B -1.52B -10.58B -4.1B -51.96B -3.99B -3.91B -169B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
